U.S. MarketsFLASH
AbbVie (ABBV) Q2 2026 (USD): Adj. EPS 3.65 (exp. 3.60), Revenue 17.0bln (exp. 16.8bln)
StockNow breaking-news AI analysis
AbbVie beat Q2 targets but narrowed its FY2026 guidance due to a $0.14 EPS dilution from the $109B Apogee acquisition, which aims to secure long-term growth through 2032.
News detail
OutlookSees FY adj. EPS at 13.87-14.07 (exp. 14.06). Includes a 0.14/shr Dilutive Impact Related to the Proposed Acquisition of Apogee Therapeutics (APOG), Which is Anticipated to Close in the Third Quarter of 2026; Includes an Unfavorable Impact of 0.58/shr Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2026
Related stocks
2 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.